Vidaza

Vidaza is a brand name of azacitidine, approved by the FDA in the following formulation(s):

VIDAZA (azacitidine - injectable; iv-sc)

• 
  Manufacturer: CELGENE
  
  Approval date: May 19, 2004
  
  Strength(s): 100MG/VIAL ^[RLD]

Has a generic version of Vidaza been approved?

No. There is currently no therapeutically equivalent version of Vidaza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vidaza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Vidaza.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 19, 2011 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Vidaza Consumer Information (Drugs.com)
• Vidaza Consumer Information (Wolters Kluwer)
• Vidaza Consumer Information (Cerner Multum)
• Vidaza AHFS DI Monographs (ASHP)
• Azacitidine Consumer Information (Wolters Kluwer)
• Azacitidine Consumer Information (Cerner Multum)
• Azacitidine Subcutaneous Advanced Consumer Information (Micromedex)
• Azacitidine AHFS DI Monographs (ASHP)